HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
This key industry gathering provided a valuable opportunity for our teams to connect with partners, customers, and key stakeholders from across the Asian eyecare and skincare ecosystems. These discussions enabled us to share insights, explore emerging trends, and identify new collaboration opportunities.
PCHi offers a unique platform to address innovation and the evolving needs of next-generation formulations. On this occasion, HTL Biotechnology showcased its expertise in high-quality biopolymers, supporting innovation in both healthcare and personal care applications.
We would like to thank everyone we met during the event for the quality of the exchanges and their interest in our solutions.
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.